Cited by 309Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in CancerHepatocellular Carcinoma Treatment and Prognosis

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

HIF Inhibitors: Status of Current Clinical Development

Fallah, Jaleh, Rini, Brian I.·2019·Current Oncology Reports

DOI 10.1007/s11912-019-0752-z

Open this paper in CoChat — free account

Abstract

Purpose of review In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed.Recent findings The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. HIF is a transcription factor which regulates the expression of genes involved in adjusting mechanisms to hypoxia such as angiogenesis or apoptosis as well as tumor growth, invasion, and metastasis. The HIF pathway has a key role in development of resistance to different treatment modalities and higher expression of the HIF molecule is associated with poor prognosis. Clinical studies of the HIF inhibitors in patients with advanced/refractory cancers suggest benefit and warrant further studies of the HIF inhibitors either as a single agent or in combination with other therapeutic agents.

Integrity signals

Registry

Crossref · 10.1007/s11912-019-0752-z

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,166
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Hypoxia-Inducible Factor 1 (HIF-1) Pathway
Semenza, G. L. (2007) · Science s STKE · doi:10.1126/stke.4072007cm8 · Cited by 970
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M. L., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Secrist, J. P., Schwartz, L. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 906

Show all 62 references

Sorted by citations

Hypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Vito, A., El-Sayes, N., & Mossman, K. L. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 287
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 270
Mitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Li, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 272
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment
Hayes, C., Donohoe, C. L., Davern, M., & Donlon, N. E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.021 · Cited by 221
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications
Wei, Q., Qian, Y., Yu, J. Q., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 193
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann‐Stemmann, T. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 205
Hypoxia-induced epithelial to mesenchymal transition in cancer
Hapke, R., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 187
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., Smaele, E. D., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 179
Crosstalk between Hypoxia and ER Stress Response: a Key Regulator of Macrophage Polarization
Díaz-Bulnes, P., Saiz, M. L., López-Larrea, C., & Rodríguez, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02951 · Cited by 175
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162
The amoeboid state as part of the epithelial-to-mesenchymal transition programme
Graziani, V., Rodríguez‐Hernández, I., Maiques, Ó., & Sanz‐Moreno, V. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.10.004 · Cited by 162
Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain
Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 178
Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing
Kabakov, A. E., & Yakimova, A. O. (2021) · Cancers · doi:10.3390/cancers13051102 · Cited by 170
The crosstalk between HIFs and mitochondrial dysfunctions in cancer development
Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03505-1 · Cited by 152
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. H. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 151
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 143
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 139
Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
Samec, M., Líšková, A., Koklesová, L., Meršaková, S., Strnádel, J., Kajo, K., Péč, M. J., Zhai, K., Šmejkal, K., Mirzaei, S., et al. (2021) · Cancers · doi:10.3390/cancers13010130 · Cited by 114
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Shurin, M. R., & Umansky, V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159473 · Cited by 113
“Alternatively, some approved drugs known to indirectly alter the HIF-1α pathway could also act as adjuvant therapy for existing cancer treatments (6).”
Background
Retinopathy of prematurity: A review of pathophysiology and signaling pathways
Fevereiro‐Martins, M., Marques‐Neves, C., Guimarães, H., & Bicho, M. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.11.007 · Cited by 115
Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies
Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115036 · Cited by 112
The role of HIF proteins in maintaining the metabolic health of the intervertebral disc
Silagi, E. S., Schipani, E., Shapiro, I. M., & Risbud, M. V. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00621-2 · Cited by 110
The interplay of hypoxic and mental stress: Implications for anxiety and depressive disorders
Burtscher, J., Niedermeier, M., Hüfner, K., van den Burg, E. H., Kopp, M., Stoop, R., Burtscher, M., Gatterer, H., & Millet, G. P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104718 · Cited by 110
Hypoxia-mediated drug resistance in breast cancers
McAleese, C. E., Choudhury, C., Butcher, N. J., & Minchin, R. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.045 · Cited by 99
Hypoxia/HIF Modulates Immune Responses
Chen, Y., & Gaber, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030260 · Cited by 100
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
Toledo, R. A., Jiménez, C., Armaiz-Peña, G., Arenillas, C., Capdevila, J., & Dahia, P. L. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac025 · Cited by 103
HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer
Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95
Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments
de la Torre, P., Pérez-Lorenzo, M. J., Alcazar-Garrido, A., & Flores, A. I. (2020) · Molecules · doi:10.3390/molecules25030715 · Cited by 96
Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment
Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 107
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89
Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer
Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., & Cai, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964934 · Cited by 83
HIF: a master regulator of nutrient availability and metabolic cross‐talk in the tumor microenvironment
Missiaen, R., Lesner, N. P., & Simon, M. C. (2023) · The EMBO Journal · doi:10.15252/embj.2022112067 · Cited by 78
WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways
Chen, T., Li, K., Liu, Z., Liu, J., Wang, Y., Sun, R., Li, Z., Qiu, B., Zhang, X., Ren, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.017 · Cited by 73
Re-engineering natural products to engage new biological targets
Motika, S. E., & Hergenrother, P. J. (2020) · Natural Product Reports · doi:10.1039/d0np00059k · Cited by 69
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions
Busk, M., Overgaard, J., & Horsman, M. R. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.05.003 · Cited by 67
Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer
Wu, D., Dasgupta, A., Read, A. D., Bentley, R. E. T., Motamed, M., Chen, K., Al‐Qazazi, R., Mewburn, J. D., Dunham‐Snary, K. J., Alizadeh, E., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.452 · Cited by 69
Hypoxia pathway proteins and their impact on the blood vasculature
Rodriguez, D., Watts, D., Gaete, D., Sormendi, S., & Wielockx, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179191 · Cited by 62
Metabolic Reprogramming in COVID-19
Shen, T., & Wang, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111475 · Cited by 61
Contribution of hypoxia inducible factor-1 during viral infections
Reyes, A., Corrales, N., Gálvez, N. M. S., Bueno, S. M., Kalergis, A. M., & González, P. A. (2020) · Virulence · doi:10.1080/21505594.2020.1836904 · Cited by 58
Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury
Li, X., Berg, N. K., Mills, T., Zhang, K., Eltzschig, H. K., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604944 · Cited by 59
Comparative Biology of Oxygen Sensing in Plants and Animals
Holdsworth, M. J., & Gibbs, D. J. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.021 · Cited by 56
Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis
Shi, Y., Gong, M., Deng, Z., Liu, H., Chang, Y., Yang, Z., & Cai, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.036 · Cited by 56
Targeting the Redox Landscape in Cancer Therapy
Narayanan, D., Ma, S., & Özcelik, D. (2020) · Cancers · doi:10.3390/cancers12071706 · Cited by 56
The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer
Metin, C. U., & Özcan, G. (2022) · Cancers · doi:10.3390/cancers14112711 · Cited by 56
P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases
Mishra, A., Behura, A., Kumar, A., Naik, L., Swain, A., Das, M., Sarangi, S. S., Dokania, P., Dirisala, V. R., Bhutia, S. K., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174235 · Cited by 53
Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis
Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00316-6 · Cited by 51
Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy
Huang, Z., Huang, S., Song, S., Ding, Y., Zhou, H., Zhang, S., Weng, L., Zhang, Y., Hu, Y., Yuan, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53084-w · Cited by 52
NADPH Oxidase 4 (NOX4) in Cancer: Linking Redox Signals to Oncogenic Metabolic Adaptation
Szántó, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052702 · Cited by 52
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 54
Self-citation
Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer
Zhao, C., Zeng, C., Ye, S., Dai, X., He, Q., Yang, B., & Zhu, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.010 · Cited by 49
Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes
Kim, I., & Park, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.025 · Cited by 49
Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer
Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030027 · Cited by 53
Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
Hensen, L. C. M., Hoeben, R. C., & Bots, S. T. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186828 · Cited by 48
Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling
Yang, H., Geng, Y., Wang, P., Zhang, H., Fang, W., & Tian, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04647-6 · Cited by 50
Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors
Casillas, A. L., Chauhan, S. S., Toth, R. K., Sainz, A. G., Clements, A. N., Jensen, C. C., Langlais, P. R., Miranti, C. K., Cress, A. E., & Warfel, N. A. (2021) · Oncogene · doi:10.1038/s41388-021-01915-1 · Cited by 44
Calpain‐1 mediates vascular remodelling and fibrosis via HIF‐1α in hypoxia‐induced pulmonary hypertension
Deng, H., Tian, X., Sun, H., Liu, H., Lü, M., & Wang, H. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17295 · Cited by 44
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 44
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities
Borde, S., & Matosevic, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.009 · Cited by 41
The potential roles of HIF-1α in epithelial-mesenchymal transition and ferroptosis in tumor cells
Shen, Z., Yu, N. H., Zhang, Y., Jia, M., Sun, Y., Li, Y., & Zhao, L. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111345 · Cited by 40
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)
Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 40
Retinal Diseases Regulated by Hypoxia—Basic and Clinical Perspectives: A Comprehensive Review
Shinojima, A., Lee, D., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235496 · Cited by 45
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer
Li, Y., Wang, J., Wang, H., Zhang, S., Wei, Y., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850093 · Cited by 40
The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis
Hudler, P., & Urbančič, M. (2022) · Genes · doi:10.3390/genes13020362 · Cited by 43
Expression and regulation of HIF-1a in hypoxic pulmonary hypertension: Focus on pathological mechanism and Pharmacological Treatment
Wan, J.-J., Yi, J., Wang, F.-Y., Zhang, C., & Dai, A.-G. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.88216 · Cited by 41
Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma
Liu, J., Chen, T., Yang, M., Zhong, Z., Ni, S., Yang, S., Shao, F., Cai, L., Bai, J., & Yu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753004 · Cited by 37
HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 35
Hypoxia-regulated microRNAs: the molecular drivers of tumor progression
Sawai, S., Wong, P., & Ramasamy, T. S. (2022) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2022.2088684 · Cited by 34
The Immunotherapy Landscape in Renal Cell Carcinoma
Brown, L. C., Desai, K. B., Zhang, T., & Ornstein, M. C. (2020) · BioDrugs · doi:10.1007/s40259-020-00449-4 · Cited by 34
HIF-1α modulates sex-specific Th17/Treg responses during hepatic amoebiasis
Groneberg, M., Hoenow, S., Marggraff, C., Fehling, H., Metwally, N. G., Hansen, C. S., Bruchhaus, I., Tiegs, G., Sellau, J., & Lotter, H. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.020 · Cited by 38
Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease
Lyu, Y., Yang, X., Yang, L., Dai, J., Qin, H., Zhou, Y., Huang, Y., Wang, Y., Wu, D., Shuai, Q., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.011 · Cited by 37
Distinct roles for the hypoxia-inducible transcription factors HIF-1α and HIF-2α in human osteoclast formation and function
Knowles, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78003-z · Cited by 35
Retinopathy of prematurity: contribution of inflammatory and genetic factors
Fevereiro‐Martins, M., Guimarães, H., Marques‐Neves, C., & Bicho, M. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04394-4 · Cited by 35
Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance
Shaikat, A. H., Azad, S. M. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., Mahmud, M. Z., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.003 · Cited by 37
Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Gain of HIF1 Activity and Loss of miRNA let-7d Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis
Wyss, C. B., Duffey, N., Peyvandi, S., Barras, D., Martínez-Usatorre, A., Coquoz, O., Romero, P. J., Delorenzi, M., Lorusso, G., & Rüegg, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-19-3560 · Cited by 33
Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells
Han, T.-H., Park, M. K., Nakamura, H., & Ban, H. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112500 · Cited by 35
Neurobiology of the carotid body
López‐Barneo, J. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-323-91534-2.00010-2 · Cited by 35
Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
Rajasegaran, T., How, C. W., Saud, A., Ali, A., & Lim, J. C. W. (2023) · Pharmaceuticals · doi:10.3390/ph16030451 · Cited by 34
Hypoxia‐Inducible Factor 1 Alpha–Mediated RelB/APOBEC3B Down‐regulation Allows Hepatitis B Virus Persistence
Riedl, T., Faure‐Dupuy, S., Rolland, M., Schuehle, S., Hizir, Z., Calderazzo, S., Zhuang, X. A., Wettengel, J. M., Lopez, M., Barnault, R., et al. (2021) · Hepatology · doi:10.1002/hep.31902 · Cited by 32
HIF-Dependent Mechanisms of Relationship between Hypoxia Tolerance and Tumor Development
Dzhalilova, D. S., & Makarova, O. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921100011 · Cited by 34
Role of dietary iron revisited: in metabolism, ferroptosis and pathophysiology of cancer.
Pandrangi, S. L., Chittineedi, P., Chikati, R., Lingareddy, J. R., Nagoor, M., & Ponnada, S. K. (2022) · PubMed · Cited by 34
Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy
Yan, T., & Shi, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509195 · Cited by 33
Sesquiterpenes and Sesquiterpene Derivatives from Ferula: Their Chemical Structures, Biosynthetic Pathways, and Biological Properties
Wang, J., Zheng, Q., Wang, H., Shi, L.-L., Wang, G., Zhao, Y., Fan, C., & Si, J. (2023) · Antioxidants · doi:10.3390/antiox13010007 · Cited by 30
Review of potential medical treatments for middle ear cholesteatoma
Schürmann, M., Goon, P. K. C., & Sudhoff, H. H. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00953-w · Cited by 31
Hypoxia-Inducible Factors Regulate Osteoclasts in Health and Disease
Meng, X., Wielockx, B., Rauner, M., & Bözec, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658893 · Cited by 28
Nuclear hormone receptor NHR-49 acts in parallel with HIF-1 to promote hypoxia adaptation in Caenorhabditis elegans
Doering, K. R. S., Cheng, X., Milburn, L. J., Ratnappan, R., Ghazi, A., Miller, D. L., & Taubert, S. (2022) · eLife · doi:10.7554/elife.67911 · Cited by 34
Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications
Jeon, S., Jeon, M., Choi, S., Yoo, S., Park, S.-H., Lee, M., & Kim, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054430 · Cited by 27
Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
Wang, Z., Zhao, Y., An, Z., & Li, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01491 · Cited by 26
Molecular Insights into the Oxygen-Sensing Pathway and Erythropoietin Expression Regulation in Erythropoiesis
Tomc, J., & Debeljak, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137074 · Cited by 28
Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia‐inducible factor‐1α in colorectal cancer
Fang, C., Dai, L., Wang, C., Fan, C., Yu, Y., Yang, L., Deng, H., & Zhou, Z. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13044 · Cited by 29
Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy
Zhang, X., He, C., & Xiang, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.012 · Cited by 28
Harnessing Natural Killer Cells for Lung Cancer Therapy
Ma, S., Caligiuri, M. A., & Yu, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1097 · Cited by 27

Authors: Fallah, J., & Rini, B. I.
Affiliations: Cleveland Clinic (US)
Corresponding author: Rini, Brian I.
ORCID: Fallah, Jaleh
Rini, Brian I.
Venue: Current Oncology Reports
Publisher: Springer Science and Business Media LLC
Published: 2019-01
Volume: 21
Issue: 1
Pages: 6-6
ISSN: 1523-3790 (ISSN-L)
1534-6269
DOI: 10.1007/s11912-019-0752-z
OpenAlex: W2913218828
Cited by: 308
References: 62
Citations by year: 2026: 10 · 2025: 20 · 2024: 43 · 2023: 52 · 2022: 68 · 2021: 64 · 2020: 45 · 2019: 5
FWCI: 4.38
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Current Oncology Reports (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords: hypoxia-inducible factor, HIF inhibitors, tumor hypoxia, VHL mutation, angiogenesis, apoptosis, metastasis, treatment resistance, advanced cancer, clinical trials, combination therapy
MeSH terms: Antineoplastic Agents, Carcinoma, Renal Cell, Clinical Trials as Topic, Humans, Kidney Neoplasms, Prognosis, Research Design, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HIF Inhibitors: Status of Current Clinical Development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks